HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation.

Abstract
The findings of our initial study demonstrate for the first time the ability to terminate induced VT/VF reliably (100% of all episodes) by a single, monophasic 230-J shock delivered by the Wearable Cardioverter-Defibrillator (WCD). Although limited by sample size, our data suggest the WCD could be used as a feasible bridge to definitive implantation of an implantable cardioverter-defibrillator in patients in whom risk stratification for sudden death is not completed.
AuthorsA Auricchio, H Klein, C J Geller, S Reek, M S Heilman, S J Szymkiewicz
JournalThe American journal of cardiology (Am J Cardiol) Vol. 81 Issue 10 Pg. 1253-6 (May 15 1998) ISSN: 0002-9149 [Print] United States
PMID9604964 (Publication Type: Clinical Trial, Journal Article)
Topics
  • Aged
  • Electric Countershock (instrumentation)
  • Electrocardiography, Ambulatory
  • Female
  • Heart Arrest (etiology, prevention & control)
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Risk
  • Ventricular Fibrillation (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: